Skip to content

EV / sales at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
-0.3×
Artivion logo
ArtivionAORT
4.3×+0.8×
AngioDynamics logo
AngioDynamicsANGO
1.4×+0.2×
AIR
AirSculpt Technologies, Inc.AIRS
1.5×+0.2×
PROCEPT BioRobotics Corporation logo
PROCEPT BioRobotics CorporationPRCT
4.6×
AtriCure logo
AtriCureATRC
2.4×-0.8×

Other financials

Income statement

See full
Revenue$12.5M+32.4%
Gross profit$7.5M-19.2%
Operating income-$5.5M-349%
Net income-$2.1M+48.6%
EPS (diluted)-$0.19-533%

Balance sheet

See full
Cash & equivalents$31.1M+0.4%
Total debt$39.5M+1.4%
Total equity$12.8M+22.1%
Total assets$63.0M+4.8%

Cash flow

See full
Operating cash flow-$572.0K+18.5%
CapEx$60.0K+9.1%
Free cash flow-$632.0K+16.5%

Valuation

See full
Market cap$181.07M+114%
Enterprise value$189.4M+101%
P/S3.2×+1.4×

Profitability

See full
Gross margin61.9%-3.1pp
Operating margin-46%+9.9pp
Net margin-16.2%-6.2pp
FCF margin-16.1%-4.8pp

Returns & leverage

See full
Return on equity-77.8%-22.4pp
Debt / equity3.1×-0.6×
Current ratio5.8×+0.3×

Where this comes from

Calculated from Apyx Medical Corporation’s reported figures.

Based on the most recent quarter.

The official record: Apyx Medical Corporation’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apyx Medical Corporation's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Apyx Medical Corporation's EV / sales?
Apyx Medical Corporation (APYX) reported EV / sales of 2.9× in Q1 2026.
How has Apyx Medical Corporation's EV / sales changed year-over-year?
Apyx Medical Corporation's EV / sales increased by 130.6% year-over-year, from 1.3× to 2.9×.
What is the long-term trend for Apyx Medical Corporation's EV / sales?
Over 5 years (2020 to 2025), Apyx Medical Corporation's EV / sales has grown at a -17.4% compound annual growth rate (CAGR), from 7.4× to 2.9×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.